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This report describes the analysis of a novel mutant
human factor IX protein from a patient with hemophilia
B (factor IX activity <1%; factor IX antigen 45%). Enzy-
matic amplification of all eight exons of the factor IX
gene followed by direct sequence analysis reveals a sin-
gle nucleotide change (a guanine 3 adenine transition)
in exon 2 at nucleotide 6409 which results in a glycine3
arginine substitution at amino acid 12 in the g-carboxy-
glutamic acid rich (Gla) domain of the mature protein.
Factor IX was isolated by immunoaffinity chromatogra-
phy from plasma obtained from the proband. The puri-
fied protein is indistinguishable from normal factor IX
by polyacrylamide gel electrophoresis. Characteriza-
tion of the variant in purified component assays reveals
that it is activated normally by its physiologic activator
factor XIa, but its phospholipid-dependent activation by
the factor VIIa-tissue factor complex is diminished. In
the presence of phospholipid and 5 mM Ca21, the activi-
ties of variant and normal plasma-derived factor IX are
similar; however, in the presence of activated factor
VIIIa (intrinsic tenase complex), the normal augmenta-
tion of the cleavage of the specific substrate of factor IX,
factor X, is not observed. The determination of the asso-
ciation constants for normal and variant factor IXa with
factor VIIIa shows that the affinity of the activated var-
iant factor IX for the cofactor factor VIIIa is 172-fold
lower than normal. Competition studies using active
site-inactivated factor IXas in the intrinsic tenase com-
plex confirm that the defect in the variant protein is in
its binding to factor VIIIa. We conclude that the struc-
tural integrity of the Gla domain of human factor IX is
critical for the normal binding of factor IXa to factor
VIIIa in the intrinsic tenase complex. In addition, a gly-
cine at amino acid 12 is necessary for normal activation
of factor IX by the factor VIIa-tissue factor complex.
Factor IX (F.IX)1 is a vitamin K-dependent trypsin-like ser-
ine protease which functions in the middle phase of blood
coagulation. F.IX is activated by either factor VIIa-tissue factor
(F.VIIa-TF) or factor XIa (F.XIa) in Ca21-dependent reactions.
Once activated, factor IXa (F.IXa), with its cofactor factor VIIIa
(F.VIIIa) in the presence of Ca21 and phospholipid, forms the
intrinsic tenase complex and is responsible for the cleavage of
the Arg52-Ile53 bond in the heavy chain of its specific substrate,
factor X (F.X), generating activated F.X (F.Xa) (F.X numbering
according to Leytus et al. (1)). Inherited deficiency of F.IX
results in a bleeding disorder, hemophilia B.
Factor IX circulates as a 415-amino acid single chain zymo-
gen with a molecular mass of 55,000 daltons and is present in
normal plasma at approximately 5 mg/ml. Factor IX is synthe-
sized in the hepatocyte as a precursor containing an amino-
terminal signal sequence and a propeptide. The signal se-
quence and propeptide are cleaved off in separate reactions
prior to secretion, and failure to remove these sequences re-
sults in a nonfunctional protein (2). The signal sequence directs
the protein to the endoplasmic reticulum (ER). The propeptide
contains elements which are important for recognition of F.IX
by the vitamin K-dependent g-glutamyl carboxylase which is
associated with the inner surface of the ER (3). The amino-
terminal 38 residues of the mature protein comprise a func-
tional region known as the Gla domain, so named because its
first 12 glutamic acid residues undergo a post-translational
vitamin K-dependent carboxylation at the g-carbon (Gla resi-
dues). The Gla domain functions in calcium-dependent lipid
binding and in binding to endothelial cells (residues 3–11) (4).
The gene encoding F.IX is present on the X chromosome at
Xq27.1 near the F.VIII locus; it spans 33.5 kilobases and is
composed of eight exons which correspond to the functional
domains of F.IX (5). Exon 1 encodes the signal peptide, exon 2
the propeptide and Gla domain, exon 3 a small aromatic amino
acid-rich domain, exons 4 and 5 the 2 epidermal growth
factor-like domains, exon 6 the activation peptide, and exons
7 and 8 the trypsin-like catalytic domain. Point mutations in
the Gla domain of F.IX (and other vitamin K-dependent
clotting factors) result in mild to severe bleeding disorders
(6–8).
This report describes a point mutation in exon 2 of the factor
IX gene which results in a glycine to arginine substitution at
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amino acid 12 in the Gla domain of mature F.IX.2 Analysis
reveals that the major defect associated with the variant pro-
tein is a markedly diminished cleavage of the substrate F.X by
F.IXa when the variant F.IXa is associated with its cofactor
F.VIIIa in the membrane-bound intrinsic tenase complex. The
data suggest that the binding of the variant F.IXa to F.VIIIa is
diminished 172-fold, and that this defect accounts for the de-
creased activity of F.IXa in the intrinsic tenase complex. In
addition, the functional characterization of this variant protein
provides evidence that this substitution affects its normal ac-
tivation by the membrane-bound F.VIIa-TF complex.
EXPERIMENTAL PROCEDURES
Materials
Taq polymerase was obtained from Perkin-Elmer, and Sequenase
was obtained from U. S. Biochemical Corp. Nonidet P-40, Fast Flow
Q-Sepharose, sodium heparin (porcine), and poly-L-lysine were obtained
from Sigma. Rabbit brain thromboplastin (Simplastin Excel) and rabbit
brain phospholipid (Platelin) were obtained from Organon Teknika,
Research Triangle Park, NC. Kaolin was obtained from Fisher. Anti-
serum to human F.IX for crossed immunoelectrophoresis was obtained
from Diagnostica Stago, Asnieres France, and polyclonal F.IX antibody
coupled to horseradish peroxidase for immunoblotting was obtained
from Dako-Patts, Carpinteria, CA. A-5 and A-7 monoclonal human F.IX
antibodies were produced as described previously (9). Coomassie pro-
tein assay was obtained from Pierce. D-Phenyl-Pro-Arg-chloromethyl
ketone, phenylmethylsulfonyl fluoride, p-nitrophenyl p-guanidinoben-
zoate, and dansyl-Glu-Gly-Arg-chloromethyl ketone (DEGR) were ob-
tained from Calbiochem. Silver staining kit was obtained from Bio-Rad.
Chemiluminescence detection system (ECL) was obtained from Amer-
sham, Buckinghamshire, United Kingdom. Spectrozyme-F.Xa was ob-
tained from American Diagnostica, Greenwich CT. Bovine brain phos-
phatidylserine and phosphatidylcholine were obtained from Avanti
Polar Lipids, Birmingham, AL. A Vmax microtiter plate reader (Molec-
ular Devices Corp., Menlo Park, CA) was used for all spectrophotomet-
ric assays.
Proteins
Monoclonally purified F.VIII (AHF-MethodM) was obtained from the
American Red Cross, Washington, D. C. Thrombin (F.IIa) and anti-
thrombin III (AT-III) were the generous gift of Dr. F. Church (Univer-
sity of North Carolina, Chapel Hill, NC). Hirudin was obtained from
Accurate Chemical and Scientific Corp., Westbury, NY. Recombinant
F.VIIa was obtained from NovoNordisk (Bagsvaerd, Denmark). Recom-
binant relipidated tissue factor was obtained from Baxter Dade (Miami,
FL). Plasma-purified human F.X was obtained from Enzyme Research
Laboratories, South Bend, IN. Normal F.IX was purified from frozen
plasma obtained from the blood bank at Children’s Hospital of
Philadelphia.
Human Subject
The affected patient is a 35-year-old male with severe hemophilia B
(,1% F.IX activity). There is no evidence of antibodies to F.IX, and his
F.IX antigen level is 45%. The subject gave his informed consent for
phlebotomy and underwent manual plasmapheresis.
Mutation Analysis
Genomic DNA was purified according to the method of Bell (10) and
stored in Tris-EDTA at 220 °C. Genomic DNA was amplified by the
polymerase chain reaction (PCR) (11). Fifty-microliter reaction mix-
tures contained 0.1 mg of genomic DNA, 0.1 mM amplification primers,
200 mM dNTP, in a buffer of 10 mM Tris, pH 8.3, 50 mM KCl, 2.5 mM
MgCl2, 0.01% gelatin. Amplification primers were derived from intron
sequences such that all exons and intron-exon junctions were amplified.
Exons 3 and 4 were amplified together, and the large exon 8 was
amplified in two fragments as described previously (12). After the
addition of 1.5 units of Taq polymerase, the reaction mixtures were
overlaid with mineral oil and heated to 94 °C for 10 min. Thirty ampli-
fication cycles were performed consisting of 2 min at 55 °C (primer
annealing), 3 min at 72 °C (primer extension), and 2 min at 94 °C
(denaturation). PCR reaction mixtures were subjected to 1% agarose gel
electrophoresis in Tris borate-EDTA buffer at 95 V. DNA bands were
visualized by ethidium bromide staining and excised. DNA was purified
from the isolated agarose fragments and resuspended in 8 ml of dis-
tilled, deionized water for dideoxy sequence analysis. Sequencing reac-
tions were carried out by adding 2 ml of 5 3 Sequenase reaction buffer
and 0.4 ml of 10% Nonidet P-40 to resuspended PCR-amplified DNA
fragments and heating to 100 °C for 3 min. Two microliters of water
were added to the reaction, and dideoxy sequencing reactions were
carried out with Sequenase according to the manufacturer’s instruc-
tions. Termination reactions were separated on a 6% denaturing poly-
acrylamide gel at 75 watts, and autoradiographs were produced by
exposing dried gels to film for 24–72 h.
F.IX Coagulation and Antigen Assays
Prothrombin time and activated partial thromboplastin time were
performed by standard tilt tube methods using rabbit brain thrombo-
plastin as reagent for the prothrombin time assay and platelin and
kaolin for the activated partial thromboplastin time. F.IX activity as-
says were performed on patient plasma diluted into F.IX-deficient
plasma using a one-stage activated partial thromboplastin time-based
assay. F.IX antigen level was determined by crossed immunoelectro-
phoresis (13) using commercially available antiserum to human F.IX.
F.IX antigen level was also determined by an enzyme-linked immuno-
assay in which the monoclonal anti-human F.IX antibody A-5 was
utilized as the capture antibody and the A-7 monoclonal anti-human
F.IX antibody as the detecting antibody.
Purification of Plasma-derived F.IX
Citrated patient plasma was stored at 218 or 280 °C until use. Forty
to sixty milliliters of plasma were thawed at 4 °C and centrifuged at
5000 3 g for 10 min to remove cryoprecipitable proteins. The cryosu-
pernatant was diluted 1:1 into 20 mM Tris, pH 7.4, and adjusted to a
concentration of 10 mM benzamidine, 1 mM EDTA, and 1 unit/ml hep-
arin. This solution was applied to 5 ml of Fast Flow Q-Sepharose
equilibrated in 20 mM Tris, pH 7.4, 150 mM NaCl, 10 mM benzamidine
at 4 °C. Beads were washed with 500 ml of 20 mM Tris, pH 7.4, 150 mM
NaCl, and 10 mM benzamidine, followed by a 30–50-ml wash with 20
mM Tris, pH 7.4, 150 mM NaCl. Protein was eluted with 20 mM Tris, pH
7.4, 750 mM NaCl at a flow rate of 0.5–1 ml/min. Four-milliliter frac-
tions were screened for protein by Coomassie assay. Fractions contain-
ing protein were pooled, added to 4 volumes of 20 mM Tris, 10 mM
benzamidine, 25 mM MgCl2, and applied, at a rapid rate, to a 2-ml
column containing agarose coupled to the A-7 metal ion-dependent
monoclonal anti-human F.IX antibody (14) (3 mg of antibody/1 ml of
agarose) which had been equilibrated in 20 mM Tris, pH 7.4, 150 mM
NaCl, 20 mMMgCl2. The column was washed with 200 ml of 20 mM Tris,
150 mM NaCl, and 20 mM MgCl2, then eluted at 22 °C with 20 mM Tris,
150 mM NaCl, 20 mM EDTA at a flow rate of 6 ml/h. Eluted protein was
detected by absorbance at 280 nm. Protein eluting in a sharp peak was
pooled, and the protease inhibitors D-phenyl-Pro-Arg-chloromethyl ke-
tone, dansyl-Glu-Gly-Arg-chloromethyl ketone, and phenylmethylsulfo-
nyl fluoride were added to a concentration of 1 mM. Purified material
was then dialyzed extensively against 20 mM Hepes, pH 7.4, 150 mM
NaCl and frozen in aliquots at 270 °C. Normal F.IX was purified in an
identical fashion from human plasma collected from volunteer whole
blood donors. Excluding thawing of plasma and dialysis, the purifica-
tion was accomplished in less than 10 h. Yields of both variant and
normal plasma protein were approximately 40–75%.
Analysis of Protein
Protein separation was performed using an 8–25% gradient SDS-
polyacrylamide gel, and protein was visualized by a commercial silver
staining method (15). Polyacrylamide gel separated protein was trans-
ferred to a nylon membrane by a semidry electrophoretic method.
Immunoblotting was performed using a chemiluminescence detection
system employing a peroxidase-conjugated polyclonal F.IX antibody.
Gla analysis was performed according to the modified alkaline hydrol-
ysis method of Price (16). Amino-terminal protein sequence analysis
was performed by automated Edman degradation to confirm the muta-
tion at position 12.
Activation of F.IX by F.XIa
F.XIa was prepared from human plasma as described previously (17).
In 200 ml of Hepes-buffered saline with albumin, 250 nM F.IX was
activated using 1 nM F.XIa. The reaction was started by the addition of
Ca21 to a concentration of 5 mM. At various time points, 10 ml were
removed and added to 190 ml of 2 mM EDTA to quench activation. F.IX
activity was determined by adding 40 ml of the quenched activation time
2 F.IX G12R. In the hemophilia B data base (6), this variant is
referred to as F.IXLos Angeles 4.
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point mixtures to 60 ml of 500 nM F.X, 1.7 mM Spectrozyme-F.Xa, 100 nM
poly-L-lysine in a microtiter plate. F.IXa-mediated activation of F.X was
detected by the release of pNA from Spectrozyme-F.Xa by generated
F.Xa and monitored by sequential spectrophotometric readings taken
over 30 min at 405 nm on a thermally controlled kinetic microtiter plate
reader at 25 °C.
Activation of F.IX by F.VIIa-TF
Factor VIIa and recombinant relipidated tissue factor were incu-
bated for 5 min at 37 °C. In a total volume of 200 ml of Hepes-buffered
saline with albumin and 3 mM Ca21, 100 nM F.IX was activated at 37 °C
with 1 nM F.VIIa and 1 nM TF (reaction was started by the addition of
F.VIIa-TF). At various time points, 10 ml of this reaction mixture were
removed and quenched with 190 ml of 2 mM EDTA. Determination of
F.IXa activity was performed as described above.
Purification of F.IXa and Determination of F.IXa Concentration
by AT-III Titration
Normal or variant F.IX was activated to completion by F.XIa as
determined by the chromogenic substrate assay. EDTA was added to
reaction mixtures to chelate Ca21. Reaction mixtures were then run
over Fast Flow Q-Sepharose equilibrated in Hepes-buffered saline with
1 mg/ml albumin and eluted with 20 mM Hepes, pH 7.4, 250 mM NaCl,
20 mM CaCl2. Fractions containing protein were pooled and dialyzed
into Hepes-buffered saline. Concentrations of these stock F.IXa solu-
tions (normal and variant) were determined by active site titration
using AT-III as described previously (12) (data not shown). Stock AT-III
solutions were titrated against p-nitrophenyl-p9-guanidinobenzoate-ti-
trated thrombin and diluted into Hepes-buffered saline containing 5
mg/ml heparin. F.IXa solutions were incubated with varying concentra-
tions of AT-III-heparin, and the concentration of AT-III required to
neutralize the activity of F.IXa completely was determined. All subse-
quent experiments were performed using these stock F.IXa solutions.
Preparation of Phospholipid Vesicles
Phospholipid vesicles consisting of a molar ratio of 30% phosphati-
dylserine:70% phosphatidylcholine (PSPC vesicles) were prepared by a
rapid extrusion procedure (18).
F.IXa Affinity for PSPC Vesicles
As a measure of F.IXa (normal and variant) affinity for phospholipid,
varying concentrations of F.IXa between 0 and 7.5 nM were used to
activate F.X. In a total reaction volume of 100 ml in Hepes-buffered
saline with albumin and 10 mM Ca21, F.IXa was incubated for 5 min at
25 °C with 40 mM PSPC vesicles. Reactions were started by the addition
of F.X for a final concentration of 100 nM and Spectrozyme-F.Xa for a
final concentration of 0.5 mM. F.X activation was detected spectropho-
tometrically using the F.Xa-specific chromogenic substrate. In this and
subsequent assays, experiments were performed in duplicate, and
curves were fitted using all data points.
Activation of F.X by F.IXa in the Presence of Phospholipid
In a 50-ml volume of Hepes-buffered saline with albumin with 10 mM
Ca21, 10 nM F.IXa (normal or variant) was incubated with 40 mM PSPC
vesicles in a microtiter plate well. Factor X (varying concentrations
between 0 and 1000 nM) and Spectrozyme-F.Xa (final concentration 1
mM) were added to this mixture, and the absorbance at 405 nm was
measured for 30 min on the kinetic plate reader.
Activation of F.X by F.IXa-F.VIIIa in the Presence of
Phospholipid (Intrinsic Tenase Complex)
Factor VIIIa was freshly prepared by incubating 16 nM monoclonal
F.VIII with 20 nM thrombin (F.IIa) for 5 min at 25 °C. After 5 min,
hirudin was added to a concentration of 50 nM to stop the reaction.
PSPC vesicles, Ca21, and 1 mM Spectrozyme-F.Xa were added to this
reaction, and 30 ml of the PSPC-F.VIIIa-Spectrozyme-F.Xa were then
added to 20 ml of F.IXa (normal or variant) in a microtiter plate well and
incubated for 5 min at 25 °C to form the intrinsic tenase complex. This
method of F.VIII activation results in a concentration of F.VIIIa that is
25% of the starting concentration of F.VIII as determined by coagula-
tion assays. The activated F.VIII retains 88% of its maximal activity at
5 min as determined by F.Xa generation in a purified component in-
trinsic tenase assay (data not shown). Intrinsic tenase activity was
detected kinetically on the microtiter plate reader upon the addition of
50 ml of F.X (varying concentration). Final concentrations were 0.1 nM
F.IXa, 0.25 nM F.VIIIa, 40 mM PSPC, 0–200 nM F.X, and 0.5 mM
Spectrozyme-F.Xa.
Binding of F.IXa to F.VIIIa
Factor VIII was activated by incubating 100 ml of F.VIII (165 nM)
with 20 nM thrombin for 5 min at 25 °C. Thrombin was then inhibited
by incubation of the F.VIIIa reaction mixture with 1900 ml of a solution
containing 50 nM hirudin, Ca21, and PSPC vesicles. Twenty-five micro-
liters of this F.VIIIa-containing solution were mixed with 25 ml of F.IXa
(varying concentration), and the reaction was incubated for 5 min at
25 °C. Activity of the intrinsic tenase formed by binding of F.VIIIa to
F.IXa was then measured by the addition of 50 ml of a mixture of F.X
and Spectrozyme-F.Xa. Reaction buffer was Hepes-buffered saline with
1 mg/ml albumin. Final concentrations were 0.5 nM F.VIIIa, F.IXa
varied between 0 and 15 nM, 40 mM PSPC, 0.5 mM Spectrozyme-F.Xa, 5
mM Ca21, 100 nM F.X.
Inhibition of F.X Activation by the Intrinsic Tenase Complex with
Active Site-inactivated F.IXa (Intrinsic Tenase Inhibition Assay)
Active site-inactivated F.IXa species (normal and variant) were pre-
pared by incubating 5 nM F.IXa with 10 mM dansyl-Glu-Gly-Arg-chlo-
romethyl ketone (DEGR) for 3 h at 37 °C. Following incubation, inacti-
vated F.IXa was dialyzed extensively against 20 mM Hepes, pH 7.4, 150
mM NaCl to remove residual free DEGR. Varying amounts of normal or
variant inactivated F.IXa (0 nM-50 nM final concentrations) were com-
bined with 50 pM normal F.IXa. The tenase complex was formed by the
addition of PSPC vesicles and F.VIIIa (freshly prepared as described
above) to the F.IXa and incubated for 5 min at 25 °C. Intrinsic tenase
activity was then measured as the rate of generation of F.Xa as detected
by the addition of F.X and Spectrozyme-F.Xa. Final concentrations were
50 pM normal F.IXa, 2.75 nM F.VIIIa, 40 mM PSPC, 100 nM F.X, 0.5 mM
Spectrozyme-F.Xa, and 5 mM Ca21.
Data Analysis
F.VIIa-TF Activation—Activation of F.IX by F.VIIa-TF fits the
equation:
relative @F.IXa# 5 1 2 e~2kt! (Eq. 1)
where k is the rate of F.IX activation (19). This equation assumes that
the rate is normalized to 1 as the maximum, and that at t0 there is no
F.IXa. Raw data can be accommodated with the equation:
~1 2 e~2kt!!~@F.IXamax# 2 @F.IXa#0! 1 @F.IXa#0 (Eq. 2)
thus, for normal F.IX, k 5 0.050; for variant F.IX, k 5 0.013.
F.IXa Activity—This is determined from a coupled assay in which
both F.X and a chromogenic substrate for F.X are added to F.IXa and
cofactors. The amount of cleavage of the chromogenic substrate is
plotted against time and fitted to the equation:
absorbance 5 a0 1 a1t 1 a2t2 (Eq. 3)
where a0 gives the amount of cleaved substrate at time 0; a1 gives the
amount of F.Xa present in the zymogen F.X, and a2 reflects the rate at
which F.Xa cleaves the chromogenic substrate, the rate at which F.X is
cleaved, and the amount of enzyme (F.IXa/PSPC) or (F.IXa-F.VIIIa/
PSPC) present in the reaction (20).
F.IXa Binding to F.VIIIa—Data are analyzed using equations de-
scribed by Krishnaswamy et al. (21) and by Duffy et al. (22). The rate of
F.Xa generation is given by
v 5 kcat @F.IXa-F.VIIIa# (Eq. 4)
The maximal rate is given by:
Vmax 5 kcat @F.IXa-F.VIIIa#max (Eq. 5)
When F.VIIIa is limiting,
Vmax 5 kcat @F.VIIIa#t (Eq. 6)










Since [F.IXa] 5 [F.IXa total] 2 [F.IXa in the intrinsic tenase complex],
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then:
@F.IXa-F.VIIIa# 5
~@F.IXa#t 2 @F.IXa-F.VIIIa#!~@F.VIIIa#t 2 @F.IXa-F.VIIIa#!
Kd
(Eq. 9)
Solving for [F.IXa-F.VIIIa] gives:
@F.IXa-F.VIIIa# 5
~@F.IXa#t 1 @F.VIIIa#t 1 Kd!
2
2
Î~@F.IXa#t 1 @F.VIIIa#t 1 Kd!2 2 4@F.IXa#t@F.VIIIa#t
2
(Eq. 10)
which can be substituted into Equation 7. Curves were derived from a
least-squares fit of the data to substituted Equation 7.
DEGR-F.IXa Inhibition of F.IXa-F.VIIIa Activity—Data are ana-
lyzed by a variation of the above scheme. Since the concentration of the
F.IXa-F.VIIIa complex is small compared to the total concentration of









z ~@F.IXa#t 2 @F.IXa-F.VIIIa#!
z ~@F.VIIIa#t 2 @F.IXa-F.VIIIa# 2 @DEGR-F.IXa-F.VIIIa#! (Eq. 12)




Kd 1 @F.VIIIa#t 2 @DEGR-F.IXa-F.VIIIa#
(Eq. 13)
Since the rate of F.Xa generation is a direct function of the amount of








relative rate 5 SKd 1 @F.VIIIa#t@F.VIIIa#t D
z S @F.VIIIa#t 2 @DEGR-F.IXa-F.VIIIa#Kd 1 @F.VIIIa#t 2 @DEGR-F.IXa-F.VIIIa#D (Eq. 15)
The concentration of DEGR-F.IXa-F.VIIIa can be determined as de-
scribed for the F.IXa-F.VIIIa complex in Equations 8–10 above assum-
ing that the concentration of the F.IXa-F.VIIIa complex is small com-
pared to the total amount of F.VIIIa and is given by the equation:
@DEGR-F.IXa-F.VIIIa# 5
~@DEGR-F.IXa#t 1 @F.VIIIa#t 1 Ki!
2
2
Î~@DEGR-F.IXa#t 1 @F.VIIIa#t 1 Ki!2 2 4@DEGR-F.IXa#t@F.VIIIa#t
2
(Eq. 16)
which can be substituted into Equation 15. Curves were derived from a
least-squares fit of the data to substituted Equation 15. Curve fits were
performed using the SlideWrite program (Advanced Graphics Software
Inc., Carlsbad, CA).
RESULTS
Direct sequence analysis of amplified genomic DNA from all
eight exons and the exon-intron junctions of the variant F.IX
gene demonstrated a single G 3 A transition at nucleotide
6409 in exon 2 (Fig. 1). The mutation was confirmed by se-
quence analysis of the opposite strand. This single nucleotide
change results in the substitution of arginine for glycine at
amino acid 12 in the Gla domain of the mature F.IX protein.
The mutation neither creates nor destroys an endonuclease
cleavage site useful for confirming the mutation by restriction
analysis.
Screening coagulation studies on patient plasma showed a
prothrombin time of 10.4 s (control 5 10.6) and a partial throm-
boplastin time of 64.9 s (control 5 37). F.IX activity was ,1%.
F.IX antigen level was 41% by crossed immunoelectrophoresis
and 45% by enzyme-linked immunosorbent assay (normal
range 60–150%).
Immunoaffinity-purified F.IX from patient plasma comi-
grated with normal F.IX on electrophoresis in an 8–25% gra-
dient SDS-polyacrylamide gel (Fig. 2). Immunoblotting con-
firmed this material to be human F.IX (data not shown). In
order to confirm the mutation, purified variant F.IX was sub-
jected to amino-terminal amino acid analysis. Edman degrada-
tion demonstrated a single amino acid species, arginine, at
position 12. Gla analysis demonstrated 9.1 mol of Gla/mol of
variant F.IX and 8.7 mol of Gla/mol of normal plasma-derived
F.IX.
F.IXa activities in the following purified component assays
were determined by the calculation of initial rates of F.IXa-
mediated activation of F.X. The optimal concentration of PSPC
vesicles (40 mM) was determined by varying the concentration
of PSPC from 5 mM to 1 mM and determining the rate of F.Xa
generation using normal F.IXa (10 nM) and normal F.X (300
nM) (data not shown). The rate of activation of purified variant
F.IX by F.XIa was identical with that of normal F.IXa (Fig. 3).
However, activation of the variant F.IX by the F.VIIa-TF com-
plex was slower (Fig. 4), approximately 25% of normal based on
kinetic analysis of time courses of activation (rate for normal
F.IX is 0.050 6 0.002 min21, for variant F.IX is 0.013 6 0.001
min21; see data analysis).
Varying F.IXa between 0 and 10 nM showed the expected
linear increase in the rate of F.Xa generation in the presence of
40 mM PSPC vesicles at 5 mM Ca21 (Fig. 5). As shown in the
inset to Fig. 5, there was no difference in F.Xa generation
between normal F.IXa and variant F.IXa at subnanomolar
concentrations (between 40 and 700 pM), indicating no defect in
phospholipid binding by the variant F.IXa. As shown in Fig. 6A,
the kinetics of F.X activation by purified variant F.IXa and
normal F.IXa in the absence of F.VIIIa (in the presence of 40
mM PSPC vesicles at 5 mM Ca21) were not significantly different
(Km 5 341 6 21.7 nM, kcat 5 9.0 3 10
24 M F.Xa s21 M21 F.IXa
for normal F.IXa; Km 5 217 6 8.3 nM, kcat 5 9.2 3 10
24 M F.Xa
s21 M21 F.IXa for variant F.IXa). These data are summarized in
Table I. When the cofactor F.VIIIa was added to the reaction to
FIG. 1. Sequence analysis of genomic DNA from the proband. A
G 3 A transition at nucleotide 6409 (denoted by arrow) results in the
substitution of arginine for glycine at amino acid 12 of the mature
protein.
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form the intrinsic tenase complex, however, the variant F.IXa
did not show the normal augmentation in the rate of cleavage
of F.X (Fig. 6B). This was due to a minor extent to a difference
in Km values (45 nM for normal F.IXa-F.VIIIa complex, 142 nM
for the variant complex), but principally to a 26-fold difference
in Vmax between normal and variant F.IXa (Fig. 6B). This
defect is the likely explanation for the patient’s severe bleeding
diathesis.
Failure of the variant F.IXa to show enhanced cleavage of
F.X in the intrinsic tenase complex may be due either to altered
affinity of variant F.IXa for the cofactor, F.VIIIa, or failure of
the variant F.IXa to undergo a required conformational change
following its binding to F.VIIIa on the phospholipid surface
(23). To determine whether diminished binding of F.IXa to
F.VIIIa was responsible for the defect in the activated variant
F.IX, we first determined Kd values for the variant and normal
F.IXas (Fig. 7). The association of F.IXa with F.VIIIa was
determined by the addition of F.VIIIa and PSPC vesicles to
varying concentrations of F.IXa and measured by the increased
activation of F.X by generated intrinsic tenase (F.IXa-F.VIIIa-
PSPC vesicles-Ca21). Both the variant and normal F.IXa
showed a similar Vmax (Vmax 5 25.7 6 0.5 for normal; Vmax 5
27.5 6 4.9 for variant); however, the Kd of the variant F.IXa for
F.VIIIa-PSPC vesicles was 172-fold higher than that of normal
F.IXa (Kd 5 30.9 6 7.27 nM; Kd 5 0.18 nM 6 0.02, respectively).
Since the kinetic parameters describing the interaction of var-
iant F.IXa are extrapolated values, we sought to corroborate
the estimated Kd using a second method. We determined Ki
values for the intrinsic tenase using normal and variant F.IXas
that had been blocked at the active site as competitive inhibi-
FIG. 2. 8–25% gradient SDS-polyacrylamide gel electrophore-
sis of purified F.IX. Protein is visualized by silver staining. Lane M,
molecular weight markers. Lane A, immunoaffinity-purified normal
plasma-derived F.IX. Lane B, immunoaffinity-purified variant F.IX.
FIG. 3. Time course of F.IX activation by F.XIa. Variant (l) and
normal (E) F.IX (250 nM) are activated by F.XIa (1 nM) at 5 mM Ca21.
Activation is complete at 20 min. F.IXa activity is expressed as the
concentration (nM) of F.Xa generated/min.
FIG. 4. Time course of F.IX activation by F.VIIa and tissue
factor. Variant (l) and normal (E) F.IX (100 nM) are activated by
F.VIIa (1 nM) and TF (1 nM) at 3 mM Ca21. F.IXa activity is expressed
as the concentration (nM) of F.Xa generated/min. The rate of activation
of variant F.IX by F.VIIa-TF is 25% that of normal (0.0506 0.002 min21
for normal F.IX and 0.013 6 0.001 min21 for the variant). Rates were
determined by a least-squares fit of the data to Equation 2 (see “Exper-
imental Procedures”).
FIG. 5. F.IXa activation of F.X in the presence of phospholipid.
Variant (l) and normal (E) F.IXa (between 0 and 7.5 nM) were used to
activate 100 nM F.X in the presence of 40 mM PSPC vesicles. The inset
shows rates of activation at subnanomolar concentrations of F.IXa
(between 0 and 1 nM).
FIG. 6. F.IXa activation of F.X. A, F.IXa (10 nM normal (E) or
variant (l)) are used to activate F.X in the presence of 40 mM PSPC
vesicles and 5 mM Ca21 and in the absence of F.VIIIa. The Km and Vmax
values of variant F.IXa are 217 6 8.3 nM and 0.546 6 0.009 nM F.Xa/
min, respectively. For normal F.IXa, the Km is 341 6 21.7 nM and the
Vmax is 0.536 6 0.017 nM F.Xa/min. B, F.IXa (0.1 nM normal (E) or
variant (l)) are used to activate F.X in the presence of 40 mM PSPC
vesicles and 5 mM Ca21 with 0.25 nM F.VIIIa (intrinsic tenase complex).
The Km for F.X of the intrinsic tenase complex containing variant F.IXa
is 142 6 10.0 nM, and the Vmax is 0.067 6 0.003 nM F.Xa/min. The Km
for F.X of the normal intrinsic tenase complex is 45 nM 6 4.6, and the
Vmax is 1.834 6 0.071 nM F.Xa/min (see Table I). Curves from which the
constants were derived were determined based on a least-squares fit of
the data to the Michaelis-Menten equation.
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tors of normal F.IXa in the intrinsic tenase complex. In this
inhibition assay, activated species of normal and variant F.IX
were inhibited by the covalent linkage of the small peptide,
dansyl-Glu-Gly-Arg (DEGR), at the active site triad. If the
defect in the variant enzyme were due to abnormal binding to
F.VIIIa, the variant would be expected to exhibit diminished or
no displacement of normal F.IXa from intrinsic tenase. If, how-
ever, the defect were due to a failure of the variant to undergo
a conformational change (upon binding of F.VIIIa) necessary
for normal activity in the intrinsic tenase complex, inactivated
variant protein would bind F.VIIIa normally and displace nor-
mal F.IXa from the intrinsic tenase complex in a fashion sim-
ilar to inactivated normal F.IXa. Varying amounts of these
active site-inactivated F.IXas were added to the intrinsic te-
nase complex consisting of F.IXa, F.VIIIa, and PSPC vesicles
(Fig. 8). Ki values determined from this intrinsic tenase inhi-
bition assay were consistent with results obtained in the bind-
ing experiment and showed a 45-fold difference between nor-
mal F.IXa (Ki 5 0.17 6 0.011 nM) and variant F.IXa (Ki 5 7.71
6 0.50 nM).
DISCUSSION
We describe a novel mutation in the gene for human blood
coagulation factor IX which results in the substitution of the
large basic amino acid, arginine, for the normal glycine at
position 12 in the Gla domain of the mature protein. This
protein is of special interest because it provides evidence that
the structural integrity of the Gla domain is critical for binding
of F.IXa to the cofactor F.VIIIa. The variant protein is secreted
into the circulation, but has no activity in coagulation. We have
characterized the effects of the substitution on the function of
the variant protein in coagulation by using immunoaffinity-
purified plasma-derived F.IX in a series of functional assays.
Other F.IX mutants reported in the Gla domain have not been
studied in purified component assays (6).
On functional analysis, the major defect of the variant F.IXa
is the absence of the normal augmentation of the F.IXa-medi-
ated activation of F.X in the presence of phospholipid, Ca21,
and the cofactor F.VIIIa (intrinsic tenase) (Fig. 6B). Phospho-
lipid binding by the variant is normal at concentrations of
F.IXa between 40 pM and 10 nM as demonstrated by F.IXa-
mediated generation of F.Xa (Fig. 5). Given the normal function
of the variant in the presence of Ca21 and phospholipid alone
(Fig. 6A), the diminished activity observed in the intrinsic
tenase complex is due to a F.VIIIa-dependent interaction of
F.IXa within the intrinsic tenase complex. This reduced activ-
ity could be due either to a defect in variant F.IXa binding to
F.VIIIa or a failure of the variant to undergo a conformational
change upon binding F.VIIIa that is necessary for normal ac-
tivity in the intrinsic tenase complex. Reduced binding of the
variant F.IXa to F.VIIIa is demonstrated by both the binding
and competitive inhibition assays. In the binding experiment,
the Kd of variant F.IXa (30.9 nM) was 172-fold higher than that
of normal F.IXa (Kd 5 0.18 nM) (Fig. 7). Under the conditions
used in this binding experiment, the Kd determined for F.VIIIa
binding by variant F.IXa exceeded the highest concentration of
variant F.IXa used in the experiment. To reasonably approach
saturating conditions with variant F.IXa in this experiment
would require concentrations of F.IXa in the range (.100 nM)
where background F.X activation by F.IXa alone would affect
the analysis of the results. In addition, under such conditions,
the concentration of F.IXa would approach the concentration of
F.X used in the assay resulting in competition between F.IXa
and F.X for phospholipid binding. The use of higher concentra-
tions of F.X to overcome this limitation would result in unmea-
surable reaction rates. The intrinsic tenase inhibition assay
was performed to overcome these limitations and to corroborate
the estimated Kd using a second method. Normal F.IXa was 45
TABLE I
Kinetic analyses of normal and variant F.IXa in the presence and absence of F.VIIIa
Km Vmax Vmax [Enzyme] kcat
a kcat/Km
b
nM nM F.Xa/min nM F.Xa/s nM
Normal F.IXa 341 6 21.7 0.536 6 0.017 0.0090 10 9.0 3 1024 2640
Normal F.IXa-F.VIIIa 45 6 4.6 1.834 6 0.071 0.0305 0.053c 0.575 12.7 3 106
Variant F.IXa 217 6 8.3 0.546 6 0.009 0.0092 10 9.2 3 1024 4240
Variant F.IXa-F.VIIIa 142 6 10.0 0.067 6 0.003 0.0012 0.001c 1.200 8.45 3 106
a Units are M F.Xa, M21 F.IXa (or F.IXa-F.VIIIa), s21.
b Units are M F.Xa, M21 F.IXa (or F.IXa-F.VIIIa), s21, M21 F.X.
c Concentrations of F.IXa-F.VIIIa complex derived from experimental conditions and Kd values of normal and variant F.IXas for F.VIIIa
(see Fig. 6).
FIG. 7. Determination of Kd for normal or variant F.IXa and
F.VIIIa. Thrombin-activated F.VIIIa (0.5 nM) is incubated with variant
(l) or normal (E) F.IXa with 40 mM PSPC vesicles and 5 mM Ca21. The
binding of F.IXa to F.VIIIa was determined by measuring intrinsic
tenase activity and detected by the generation of F.Xa. The Vmax for
normal F.IXa is 25.7 6 0.5 nM F.Xa/min and for variant is 27.5 6 4.9 nM
F.Xa/min. The Kd describing the binding of normal F.IXa to PSPC-
F.VIIIa is 0.18 6 0.02 nM; for variant F.IXa, the Kd is 30.9 6 7.3 nM as
determined from curves derived from least-squares fit of the data to
Equation 7 (see “Experimental Procedures”).
FIG. 8. Inhibition of the normal intrinsic tenase complex by
dansyl-Glu-Gly-Arg (DEGR) inactivated F.IXas. Increasing con-
centrations of DEGR-inactivated F.IXa normal (E) and variant (l) are
used as competitors for normal F.IXa in the intrinsic tenase complex (50
pM F.IXa, 0.55 nM F.VIIIa, 40 mM PSPC vesicles, 5 mM Ca21). Binding
of the inactivated species is measured by the inhibition of F.Xa gener-
ation by the normal intrinsic tenase complex. Ki for DEGR-inactivated
F.IXa normal is 0.17 6 0.01 nM and for DEGR-inactivated F.IXa variant
is 7.71 6 0.50 nM as determined from curves derived from least-squares
fit of the data to Equation 15 (see “Experimental Procedures”).
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times more effective as an inhibitor in the intrinsic tenase
inhibition assay (Ki 5 0.17 nM for normal F.IXa and 7.71 nM for
variant F.IXa) (Fig. 8). Several groups have published con-
stants between 0.02 and 16 nM describing the interaction of
F.VIIIa with F.IXa under conditions different from those used
in the experiments described here (22, 24–28). Our values are
at the lower limit of other reported ranges for binding constants
but are not inconsistent with previous studies which evaluated
human factors (25, 27). In the inhibition assay, similar Ki
values (similar inhibition pattern) would have been expected
for both the normal and variant if the defect observed in the
intrinsic tenase (Fig. 6B) were due solely to the variant’s failure
to undergo the necessary conformational change. If one as-
sumes that there is no effect of the small peptide blocking the
active site of F.IXa on the binding of inactivated F.IXa (normal
or variant) to F.VIIIa, then the intrinsic tenase inhibition as-
say, in which F.X activation is accomplished only by normal
F.IXa, measures only the difference in binding of F.VIIIa be-
tween normal and variant F.IXa. Factor X activation in the
binding assay, however, relies on the measurement of F.X
activation by either normal F.IXa or variant F.IXa and, there-
fore, measures both binding and conformational effects. Thus,
the inhibition assay confirms that the major effect is due to
abnormal binding of variant F.IXa to F.VIIIa. The 4-fold dis-
crepancy between the relative differences in the normal and
variant Ki values (45-fold) and the normal and variant Kd
values (172-fold) ascertained in these two experiments is likely
to be within the range of experimental error. Alternatively,
there may be a small contribution to the defect from differences
in the conformational change undergone by wild-type versus
variant F.IXa upon binding to F.VIIIa. (A conformational dif-
ference would be reflected in the binding assay shown in Fig. 7,
but not in the competitive inhibition assay shown in Fig. 8.) In
any case, it is clear that the major factor accounting for the
reduced activity in the intrinsic tenase complex is altered bind-
ing of the variant F.IXa to F.VIIIa.
Catalytic efficiencies (kcat/Km) were calculated from experi-
mentally determined Km and Vmax (Table I). In the experi-
ments characterizing F.IXa activity in the intrinsic tenase com-
plex, the true enzyme is the F.IXa-F.VIIIa complex. The
concentration of the F.IXa-F.VIIIa complex was determined
using observed Kd values (Fig. 7) and Equation 10 (see “Exper-
imental Procedures,” Data Analysis). Note that the 172-fold
difference between the Kd values for normal and variant F.IXa
results in a marked difference in the concentration of the true
enzyme complex (normal or variant F.IXa-F.VIIIa) at identical
concentrations of F.IXa and F.VIIIa. In contrast to the differ-
ence in rates of F.X activation at a given concentration of F.IXa
between the normal and variant intrinsic tenase (Fig. 6B),
catalytic efficiencies of the normal and variant complexes are
similar, since they are determined using concentrations of the
true enzyme complex (Table I).
In the solution phase activation of F.IX by F.XIa in which
two bonds in the catalytic domain of F.IX (Arg145-Ala146 and
Arg180-Val181) are cleaved by F.XIa, variant F.IX is activated
normally. However, in the phospholipid-dependent activation
of F.IX by the F.VIIa-TF complex, in which the same two bonds
are cleaved, the variant is activated at a rate which is 25% of
normal. These data suggest that amino acid 12 of F.IX is either
involved in the binding site for F.VIIa-TF or has distal effects
on the conformation of the F.VIIa-TF binding site on phospho-
lipid-bound F.IX.
The substitution of arginine, a bulky negatively charged
residue, for the small neutral glycine at position 12 would be
predicted to affect Ca21 binding by perturbing the surrounding
Gla residues. Such an effect might be expected to result in
altered phospholipid binding since Ca21 binding in the Gla
domain is responsible for a conformational change which is
necessary for coagulant activity (29–32), and this activity is
correlated to phospholipid binding (33). However, when the
kinetic activation of F.X by F.IXa was studied with phospho-
lipid and Ca21, there was little difference between the variant
and normal F.IXa, implying that binding of the variant to F.X
and phospholipid is normal and that the effect of the amino
acid substitution has minimal, if any, effect on calcium binding.
The data indicate that the variant F.IX undergoes g-carbox-
ylation to the same degree as the normal protein. Based on
extensive work with recombinant proteins (3, 34–36) and syn-
thetic peptides (37, 38), the g-glutamyl carboxylase recognition
site is known to include residues at the amino-terminal portion
of the propeptide in vitamin K-dependent proteins. Observa-
tions from naturally occurring F.IX variants with mutations
affecting residues 21 and 24 at the carboxyl terminus of the
propeptide, are not consistent; some have reported normal
g-carboxylation (39, 40) and others, reduced g-carboxylation (2,
41). Peptide substrates which contain these same changes,
however, have no effect on carboxylation (38, 42). Although a
contribution to the carboxylase binding site from the Gla do-
main has been suggested based on sequence homology between
vitamin K-dependent coagulation factors and matrix Gla pro-
tein (43), peptide substrates which include the propeptide and
this purported binding site in the Gla domain have not been
shown to affect carboxylase binding when compared to the
propeptide substrate alone (44). Zhang et al. (45) have observed
that only 10–20% of recombinant protein C containing substi-
tutions of aspartic acid for Gla residues 16, 20, and 26 is fully
carboxylated. These data have led to the hypothesis that amino
acid substitutions which perturb the structure of the Gla do-
main or the intervening portion of the propeptide may affect
carboxylation. Normal carboxylation of the variant F.IX de-
scribed here indicates that glycine 12 is not involved in carbox-
ylase recognition, and that a nonconservative amino acid sub-
stitution at this position in F.IX does not affect g-carboxylation
of the appropriate glutamic acid residues by the carboxylase.
Alignment of the amino acid sequences of the human vitamin
K-dependent factors (F.IX, prothrombin, F.VII, F.X, protein C,
and protein S) reveals that the residue corresponding to glycine
12 of mature factor IX is conserved in these proteins, with the
exception of protein C in which another small neutral polar
amino acid (serine) is present. This suggests a critical role
for glycine (or serine) at this position. Two other mutations
have been reported in F.IX affecting amino acid 12 (6, 46). In
F.IXHong Kong1, an alanine substitution results in a molecule
with 3% normal activity. F.IXUK182, in which the charged res-
idue, glutamic acid, is substituted for glycine 12, has ,1%
normal activity. The mechanism for defective activity has not
been characterized for either of these variants.
The data presented here demonstrate that a glycine to argi-
nine substitution at position 12 in human F.IX prevents the
normal augmentation of activity of activated F.IX that occurs
in the presence of the cofactor F.VIIIa. Competition studies
with active site-inactivated F.IXa provide strong evidence that
variant F.IXa binding to F.VIIIa is diminished and accounts for
the severe defect in the activity of the variant F.IXa in the
intrinsic tenase complex. These data thus indicate a critical
role for the structural integrity of the Gla domain in the bind-
ing of F.VIIIa by F.IXa. Although it is possible that the Gla
domain of F.IXa contacts the F.VIIIa molecule directly, it is
more likely that the alignment of proper intermolecular contact
points is critically dependent on residue 12 of F.IXa, and that
the Gly 3 Arg mutation exerts its effect on F.VIIIa binding
through this mechanism.
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